COVID-19: Coronavirus Vaccine Development Updates

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Jan 11

PMID 33424848

Citations 105

Authors

Jing Zhao

Shan Zhao

Junxian Ou

Jing Zhang

Wendong Lan

Wenyi Guan

Xiaowei Wu

Yuqian Yan

Wei Zhao

Jianguo Wu

James Chodosh

Qiwei Zhang

Affiliations

Soon will be listed here.

Abstract

Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a newly emerged coronavirus, and has been pandemic since March 2020 and led to many fatalities. Vaccines represent the most efficient means to control and stop the pandemic of COVID-19. However, currently there is no effective COVID-19 vaccine approved to use worldwide except for two human adenovirus vector vaccines, three inactivated vaccines, and one peptide vaccine for early or limited use in China and Russia. Safe and effective vaccines against COVID-19 are in urgent need. Researchers around the world are developing 213 COVID-19 candidate vaccines, among which 44 are in human trials. In this review, we summarize and analyze vaccine progress against SARS-CoV, Middle-East respiratory syndrome Coronavirus (MERS-CoV), and SARS-CoV-2, including inactivated vaccines, live attenuated vaccines, subunit vaccines, virus like particles, nucleic acid vaccines, and viral vector vaccines. As SARS-CoV-2, SARS-CoV, and MERS-CoV share the common genus, , this review of the major research progress will provide a reference and new insights into the COVID-19 vaccine design and development.

Citing Articles

Antibody-dependent enhancement of coronaviruses.

Tao T, Tian L, Ke J, Zhang C, Li M, Xu X Int J Biol Sci. 2025; 21(4):1686-1704.

PMID: 39990674 PMC: 11844293. DOI: 10.7150/ijbs.96112.

The acceptance of COVID-19 vaccines in Rwanda: a cross-sectional study.

Mbonigaba E, Yu F, Renosa M, Mwikarago I, Cho F, Elad P BMC Public Health. 2024; 24(1):2875.

PMID: 39425074 PMC: 11490121. DOI: 10.1186/s12889-024-20417-9.

From ancient remedies to modern miracles: tracing the evolution of vaccines and their impact on public health.

Kajal , Pandey A, Mishra S 3 Biotech. 2024; 14(10):242.

PMID: 39319014 PMC: 11417089. DOI: 10.1007/s13205-024-04075-7.

Synthesis of a dendritic cell-targeted self-assembled polymeric nanoparticle for selective delivery of mRNA vaccines to elicit enhanced immune responses.

Fan C, Wang S, Chung C, Chen J, Chang C, Chen Y Chem Sci. 2024; 15(29):11626-11632.

PMID: 39055027 PMC: 11268467. DOI: 10.1039/d3sc06575h.

Surveillance Metrics and History of the COVID-19 Pandemic in Central Asia: Updated Epidemiological Assessment.

Lundberg A, Ozer E, Wu S, Soetikno A, Welch S, Liu Y JMIR Public Health Surveill. 2024; 10:e52318.

PMID: 39013115 PMC: 11391161. DOI: 10.2196/52318.

References

Jia W, Channappanavar R, Zhang C, Li M, Zhou H, Zhang S . Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection. Emerg Microbes Infect. 2019; 8(1):760-772. PMC: 6542157. DOI: 10.1080/22221751.2019.1620083. View

Kim E, Okada K, Kenniston T, Raj V, AlHajri M, Farag E . Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. Vaccine. 2014; 32(45):5975-82. PMC: 7115510. DOI: 10.1016/j.vaccine.2014.08.058. View

Escriou N, Callendret B, Lorin V, Combredet C, Marianneau P, Fevrier M . Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. Virology. 2014; 452-453:32-41. PMC: 7111909. DOI: 10.1016/j.virol.2014.01.002. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Tsunetsugu-Yokota Y, Ohnishi K, Takemori T . Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine. Rev Med Virol. 2006; 16(2):117-31. PMC: 7169118. DOI: 10.1002/rmv.492. View

Liu D, Fung T, Chong K, Shukla A, Hilgenfeld R . Accessory proteins of SARS-CoV and other coronaviruses. Antiviral Res. 2014; 109:97-109. PMC: 7113789. DOI: 10.1016/j.antiviral.2014.06.013. View

Pallesen J, Wang N, Corbett K, Wrapp D, Kirchdoerfer R, Turner H . Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 2017; 114(35):E7348-E7357. PMC: 5584442. DOI: 10.1073/pnas.1707304114. View

Nichols W, Ledwith B, Manam S, Troilo P . Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci. 1995; 772:30-9. DOI: 10.1111/j.1749-6632.1995.tb44729.x. View

Du L, Zhao G, Chan C, Li L, He Y, Zhou Y . A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. Viral Immunol. 2010; 23(2):211-9. PMC: 2883479. DOI: 10.1089/vim.2009.0090. View

10.

Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z . Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020; 324(10):951-960. PMC: 7426884. DOI: 10.1001/jama.2020.15543. View

11.

Takasuka N, Fujii H, Takahashi Y, Kasai M, Morikawa S, Itamura S . A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol. 2004; 16(10):1423-30. PMC: 7108621. DOI: 10.1093/intimm/dxh143. View

12.

Shi J, Zhang J, Li S, Sun J, Teng Y, Wu M . Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases. PLoS One. 2015; 10(12):e0144475. PMC: 4671582. DOI: 10.1371/journal.pone.0144475. View

13.

Feng L, Wang Q, Shan C, Yang C, Feng Y, Wu J . An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nat Commun. 2020; 11(1):4207. PMC: 7442803. DOI: 10.1038/s41467-020-18077-5. View

14.

Jimenez-Guardeno J, Regla-Nava J, Nieto-Torres J, DeDiego M, Castano-Rodriguez C, Fernandez-Delgado R . Identification of the Mechanisms Causing Reversion to Virulence in an Attenuated SARS-CoV for the Design of a Genetically Stable Vaccine. PLoS Pathog. 2015; 11(10):e1005215. PMC: 4626112. DOI: 10.1371/journal.ppat.1005215. View

15.

Ruch T, Machamer C . The coronavirus E protein: assembly and beyond. Viruses. 2012; 4(3):363-82. PMC: 3347032. DOI: 10.3390/v4030363. View

16.

Nieto-Torres J, DeDiego M, Verdia-Baguena C, Jimenez-Guardeno J, Regla-Nava J, Fernandez-Delgado R . Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog. 2014; 10(5):e1004077. PMC: 4006877. DOI: 10.1371/journal.ppat.1004077. View

17.

Corbett K, Flynn B, Foulds K, Francica J, Boyoglu-Barnum S, Werner A . Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020; 383(16):1544-1555. PMC: 7449230. DOI: 10.1056/NEJMoa2024671. View

18.

Roberts A, Lamirande E, Vogel L, Jackson J, Paddock C, Guarner J . Animal models and vaccines for SARS-CoV infection. Virus Res. 2007; 133(1):20-32. PMC: 2323511. DOI: 10.1016/j.virusres.2007.03.025. View

19.

Ng O, Chia A, Tan A, Jadi R, Leong H, Bertoletti A . Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine. 2016; 34(17):2008-14. PMC: 7115611. DOI: 10.1016/j.vaccine.2016.02.063. View

20.

de Alwis R, Gan E, Chen S, Leong Y, Tan H, Zhang S . A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. Mol Ther. 2021; 29(6):1970-1983. PMC: 8019652. DOI: 10.1016/j.ymthe.2021.04.001. View